# Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers

> **NCT01497392** · PHASE1 · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 26 (actual)

## Conditions studied

- Adenocarcinoma of the Pancreas
- Stage III Pancreatic Cancer
- Stage IV Pancreatic Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** dovitinib lactate
- **DRUG:** gemcitabine hydrochloride
- **DRUG:** capecitabine
- **OTHER:** laboratory biomarker analysis
- **OTHER:** enzyme-linked immunosorbent assay
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT01497392
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03-29
- **Primary completion:** 2015-08-31
- **Final completion:** 2017-02-07
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2022-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01497392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01497392, "Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01497392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*